CRISPR Therapeutics registers Phase 1/2 trial of CTX340 for treatment-resistant hypertensionAug 11Trial updateCRISPR Therapeutics AGCTX340
Kardigan advances three late-stage cardiovascular trials, reports $660.7M cashAug 11Quarterly updatedanicamtivKardigan
CRISPR Therapeutics reports Q2 2026 results, expanded CASGEVY approval and new trial startsAug 3Quarterly updateCRISPR Therapeutics AGCTX340
Alnylam cuts 2026 TTR revenue outlook, advances Alzheimer's and rare disease pipelineJul 30Quarterly updateAlnylam Pharmaceuticals
Sign inSign in